BMO Capital Initiates Coverage On Metagenomi with Outperform Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris initiates coverage on Metagenomi (NASDAQ:MGX) with an Outperform rating and a price target of $22.
March 05, 2024 | 11:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has initiated coverage on Metagenomi with an Outperform rating and a price target of $22.
The initiation of coverage by BMO Capital with an Outperform rating and a significant price target suggests a positive outlook for Metagenomi's stock. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100